Domov › Nemalobunkový karcinóm pľúc › Pennsylvania › Pittsburgh
Klinické štúdie Nemalobunkový karcinóm pľúc v meste Pittsburgh, PA
48 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v meste Pittsburgh a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Prebieha náborFáza 1/2
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Prebieha náborFáza 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- a 11 ďalších
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Prebieha náborFáza 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- a 8 ďalších
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Prebieha náborFáza 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Prebieha náborFáza 1
- Exelixis Clinical Site #32, Pittsburgh
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Prebieha náborFáza 2
- AHN Cancer Institute - Allegheny General ( Site 9501), Pittsburgh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Prebieha náborFáza 3
- UPMC Hillman Cancer Center, Pittsburgh
- Bryn Mawr Hospital, Bryn Mawr · 11 míľ odtiaľ
- UPMC Hillman Cancer Center - Monroeville, Monroeville · 11 míľ odtiaľ
- a 1 ďalších
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Prebieha náborFáza 3
- Local Institution - 0028, Pittsburgh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Prebieha náborFáza 1
- Research Site, Pittsburgh
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Prebieha náborFáza 1
- Research Site, Pittsburgh
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Prebieha náborFáza 2
- Bryn Mawr Hospital, Bryn Mawr · 11 míľ odtiaľ
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- AHN Allegheny General Hospital, Pittsburgh
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Prebieha náborFáza 2
- Research Site, Pittsburgh
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Prebieha náborFáza 2/3
- West Penn Allegheny Health, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Prebieha náborFáza 1/2
- Allegheny Health Network, Pittsburgh
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Prebieha náborFáza 3
- Clinical Study Site, Pittsburgh
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Prebieha náborFáza 1
- UPMC, Pittsburgh
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Prebieha náborFáza 2/3
- Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Prebieha náborFáza 1/2
- Allegheny Singer, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Prebieha náborFáza 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- Allegheny Cancer Center, Pittsburgh
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Prebieha náborFáza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Prebieha náborFáza 1/2
- University of Pittsburgh Medical Center, Pittsburgh
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Prebieha náborFáza 1
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Prebieha náborFáza 1
- UPMC, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Research Site, Pittsburgh
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Prebieha náborFáza 1/2
- Allegheny Health Network, Pittsburgh
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Prebieha náborFáza 3
- UPMC-Shadyside Hospital, Pittsburgh
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Prebieha náborFáza 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Prebieha náborFáza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Prebieha náborFáza 2
- Allegheny General Hospital, Natrona Heights · 19 míľ odtiaľ
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Prebieha náborFáza 3
- AHN Cancer Center, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Prebieha náborFáza 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Prebieha náborFáza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Prebieha náborFáza 1
- UPMC Hillman Cancer Center, Pittsburgh
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Prebieha náborFáza 1
- UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- a 11 ďalších
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- Research Site, Pittsburgh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2/3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- a 9 ďalších
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Prebieha náborFáza 3
- Allegheny, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Prebieha náborFáza 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
Prebieha náborFáza 1
- UPMC- Hillman Cancer Center, Pittsburgh
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
Prebieha náborFáza 2
- UPMC Hillman Cancer Center, Pittsburgh
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Prebieha náborFáza 1
- Hillman Cancer Center, Pittsburgh
Impact of Circadian Rhythm on Immunotherapy
Prebieha náborFáza 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Prebieha náborFáza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Prebieha náborFáza 2
- UPMC Hillman Cancer Center, Pittsburgh
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Prebieha náborFáza 1
- UPMC Hillman Cancer Center, Pittsburgh
Štúdie Nemalobunkový karcinóm pľúc v iných mestách
- Houston, TX145 štúdií
- New York City, NY121 štúdií
- Arlington, VA104 štúdií
- Nashville, TN97 štúdií
- Boston, MA90 štúdií
- Los Angeles, CA87 štúdií
- St. Louis, MO73 štúdií
- Chicago, IL61 štúdií
- Baltimore, MD60 štúdií
- San Antonio, TX59 štúdií
- Columbus, OH57 štúdií
- Washington, DC55 štúdií
Iné štúdie v Pittsburgh
- Rakovina (všetky typy)41 štúdií
- Rakovina prsníka39 štúdií
- Kolorektálny karcinóm32 štúdií
- Metastatická rakovina31 štúdií
- Melanóm31 štúdií
- Rakovina vaječníkov30 štúdií
- Rakovina endometria23 štúdií
- Rakovina prostaty23 štúdií
- Rakovina pľúc23 štúdií
- Skvamóznocelulárny karcinóm hlavy a krku22 štúdií
- Cievna mozgová príhoda22 štúdií
- Depresia22 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.